A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. - Wikidata - awgldk - TriplyDB

A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.

A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.

http://www.wikidata.org/entity/Q33423308

about

Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.

P2860

Q47093550-D7294947-40DB-4851-A34D-3F44141C22EB Q50221869-EB9C37E6-8274-42F7-B65E-10B609E281E6

P2860

A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.

http://www.wikidata.org/entity/Q33423308

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A systematic review of gemcita ...... for metastatic breast cancer.

@ast

A systematic review of gemcita ...... for metastatic breast cancer.

@en

type

label

A systematic review of gemcita ...... for metastatic breast cancer.

@ast

A systematic review of gemcita ...... for metastatic breast cancer.

@en

prefLabel

A systematic review of gemcita ...... for metastatic breast cancer.

@ast

A systematic review of gemcita ...... for metastatic breast cancer.

@en

P1433

Q33423308-C5712E46-F65C-4175-9E10-76F741239C91

P1476

Q33423308-D37575D0-BBBF-42E0-A9DC-D12D519441EF

P2093

Q33423308-0DFA512D-B95E-4CD5-B787-397995188B6F

Q33423308-2467A462-27A3-4AE3-A28C-893A6430D7FC

Q33423308-2EFECAC4-350F-4AA6-8070-9F2DC2C024B1

Q33423308-37B7A1BA-E195-4AEE-BF01-B247D26DC5BF

Q33423308-3A87967C-50D6-47B6-AEB8-F976C3EEDE26

Q33423308-AB4CAB32-8B14-42E6-91AB-B0869A2AACAB

Q33423308-BA32E840-75B0-43A9-AA59-63882553B206

Q33423308-C482AE05-7398-4094-816B-9F3B5E8E3513

Q33423308-E061809A-814B-4309-AC7A-555219F5272F

P2860

Q33423308-07676E8B-C1AA-4B9C-98E1-70D7F235F943

Q33423308-09106B9A-54A9-4E89-BEA8-EF2ED101237C

Q33423308-0BDE1F63-F8FE-465B-8146-0E902805AFCD

Q33423308-18FADAC6-118D-4DA3-8EBB-DD9DD6655103

Q33423308-19BD1FF7-2706-4E75-AD5B-9CA9405F0FDD

Q33423308-31771F1C-1A76-4190-9F08-94031674834D

Q33423308-350E8C68-38A9-4B15-81DB-AAE7A421A794

Q33423308-3F13084C-0E86-467F-B6D4-A561554E9EB8

Q33423308-44C5D444-5BAC-4087-BB64-56ABD0CF1D8C

Q33423308-4790F510-34DE-4794-A633-B0B21D9DE1DB

P2888

Q33423308-717B76AA-19FA-4364-B90B-A01BF91C8248

P304

Q33423308-2E259DDF-3D25-4EBA-8793-ACB18243A8A0

P31

Q33423308-7883EB43-3627-4EE3-8B31-3C6A3A20E033

P356

Q33423308-DE82A1F9-4A77-4C8A-8F43-8078BA64F9A3

P478

Q33423308-9E646D30-B735-4393-BCB2-3ED9924D6F8C

P577

Q33423308-E70CA419-0900-45F8-8DF5-4E3CF1E21D8A

P5875

Q33423308-5E98C79E-78ED-49DC-A132-F86F16E63D63

P6179

Q33423308-9FB81A79-8B43-4625-94DE-CFCE41F03CFB

P698

Q33423308-850A3DAA-4E11-48F5-BCE7-751DC4EF6585

P932

Q33423308-C70C2E6B-B48C-42E8-93F7-431F5A761A64

P356

2193-1801-3-293

P1433

P1476

A systematic review of gemcita ...... for metastatic breast cancer.

@en

P2093

He-Rui Yao

http://www.w3.org/2001/XMLSchema#string

Jun-Xia Jiang

http://www.w3.org/2001/XMLSchema#string

Jun-Yan Wu

http://www.w3.org/2001/XMLSchema#string

Long Luo

http://www.w3.org/2001/XMLSchema#string

Qian Hu

http://www.w3.org/2001/XMLSchema#string

Wei Zhang

http://www.w3.org/2001/XMLSchema#string

Xiao Lin

http://www.w3.org/2001/XMLSchema#string

Xiao-Xiao Dinglin

http://www.w3.org/2001/XMLSchema#string

Xing Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2008

Meta-analysis in clinical trials

Gemcitabine in the management of metastatic breast cancer: a systematic review.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.

P2888

2193-1801-3-293

P304

293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2193-1801-3-293

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274364512

http://www.w3.org/2001/XMLSchema#string

P6179

1010771925

http://www.w3.org/2001/XMLSchema#string

P698

26034661

http://www.w3.org/2001/XMLSchema#string

P932

4447724

http://www.w3.org/2001/XMLSchema#string